OBJECTIVE: To determine whether comorbid anxiety alters response to methylphenidate (MPH) in children with attention-deficit hyperactivity disorder (ADHD). METHOD: Ninety-one children with ADHD were assessed for anxiety. Children were randomly assigned to receive MPH or placebo, titrated to a dose of 0.7 mg/kg, while side effects were minimized. Measures of side effects and behavioral response were obtained from parents and teachers before treatment, after titration to optimal dose, and after 4 months of treatment. These measures, dose of drug, and rate of adherence to assigned medication assignment were compared for nonanxious (ADHD- ANX) and anxious ADHD children (ADHD+ ANX). RESULTS: Rates of adherence to original medication assignment did not differ between the groups. ADHD+ ANX on both MPH and placebo titrated to a lower dose at the end of titration, although the dose of drug did not differ among the groups after 4 months of treatment. No differential response to MPH between ADHD+ ANX and ADHD- ANX was noted at end-titration or at 4 months on any side effect or behavioral measures. CONCLUSIONS: Comorbid anxiety does not appear to influence development of side effects or behavioral response to MPH when dose is titrated as in standard clinical practice.
RCT Entities:
OBJECTIVE: To determine whether comorbid anxiety alters response to methylphenidate (MPH) in children with attention-deficit hyperactivity disorder (ADHD). METHOD: Ninety-one children with ADHD were assessed for anxiety. Children were randomly assigned to receive MPH or placebo, titrated to a dose of 0.7 mg/kg, while side effects were minimized. Measures of side effects and behavioral response were obtained from parents and teachers before treatment, after titration to optimal dose, and after 4 months of treatment. These measures, dose of drug, and rate of adherence to assigned medication assignment were compared for nonanxious (ADHD- ANX) and anxious ADHDchildren (ADHD+ ANX). RESULTS: Rates of adherence to original medication assignment did not differ between the groups. ADHD+ ANX on both MPH and placebo titrated to a lower dose at the end of titration, although the dose of drug did not differ among the groups after 4 months of treatment. No differential response to MPH between ADHD+ ANX and ADHD- ANX was noted at end-titration or at 4 months on any side effect or behavioral measures. CONCLUSIONS: Comorbid anxiety does not appear to influence development of side effects or behavioral response to MPH when dose is titrated as in standard clinical practice.
Authors: J S March; J M Swanson; L E Arnold; B Hoza; C K Conners; S P Hinshaw; L Hechtman; H C Kraemer; L L Greenhill; H B Abikoff; L G Elliott; P S Jensen; J H Newcorn; B Vitiello; J Severe; K C Wells; W E Pelham Journal: J Abnorm Child Psychol Date: 2000-12
Authors: Tanya E Froehlich; William B Brinkman; James L Peugh; Alexandra N Piedra; Daniel J Vitucci; Jeffery N Epstein Journal: J Child Adolesc Psychopharmacol Date: 2019-12-16 Impact factor: 2.576
Authors: Vishal Madaan; Joan Daughton; Brian Lubberstedt; Andy Mattai; Brigette S Vaughan; Christopher J Kratochvil Journal: CNS Drugs Date: 2008 Impact factor: 5.749
Authors: Sheila P Garcia; Julia Guimarães; Juliana F Zampieri; Ana Luiza Martinez; Guilherme Polanczyk; Luis Augusto Rohde Journal: J Neural Transm (Vienna) Date: 2009-04-16 Impact factor: 3.575